The Gamaleya Institute of Russian will submit its application for an emergency use authorization (EUA) for its vaccine for the coronavirus disease 2019 (Covid-19).
An official of the Department of Science and Technology (DOST) on Friday said Gamaleya also withdrew its intention to conduct Phase 3 trials of its candidate Covid-19 vaccine in the Philippines.
“They are already applying for emergency use authorization that’s why they will no longer have clinical trials here,” said DOST Undersecretary Rowena Guevarra in a press briefing.
She said the Russian vaccine developer will submit its EUA application on Saturday.
BesideS Gamaleya, the other Covid-19 vaccine developers seeking a EUA from the Food and Drugs Administration are United Kingdom’s AstraZeneca, United States-based Pfizer and Jannsen, and China’s Sinovac.
The government has allocated at least P72.5 billion for the purchase of Covid-19 vaccines to inoculate at least 60 percent of the country’s population.
There is also a growing list of local government units allocating their own funds to purchase Covid-19 vaccines. SOVEREIGNPH